AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
OPKO Health and Entera Bio present new data at ENDO 2025 annual meeting.
ByAinvest
Wednesday, Jun 25, 2025 8:03 am ET1min read
OPKO Health and Entera Bio announced new in vivo data for oral OPK-88006, a dual agonist GLP-1/glucagon peptide for obesity and metabolic disorders. The data will be presented at the ENDO 2025 annual meeting. Oral OPK-88006 is a tablet treatment being developed through a collaboration and license agreement between the two companies.
OPKO Health (NASDAQ: OPK) and Entera Bio announced the selection of their abstract for oral presentation at the ENDO 2025 annual meeting. The abstract details new in vivo data for OPK-88006, a novel dual GLP-1/glucagon peptide treatment for obesity and metabolic disorders [1]. This oral treatment, being developed as a once-daily tablet and a weekly subcutaneous injection, combines OPKO's long-acting oxyntomodulin analog with Entera's N-Tab™ technology.The presentation, scheduled for July 13, 2025, will showcase the pharmacologic and pharmacokinetic data of OPK-88006. The companies plan to file an Investigational New Drug (IND) application with the FDA later in 2025, followed by Phase 1 clinical studies. This marks a significant milestone in the development of OPK-88006, which aims to address the growing market for obesity therapeutics [2].
The oral delivery format of OPK-88006 represents a potential advantage over current market-leading injectable GLP-1 agonists. An effective oral alternative could capture substantial market share if it demonstrates comparable efficacy with improved convenience and tolerability. The dual-mechanism approach of OPK-88006, which includes glucagon activation, could enhance metabolic benefits beyond what GLP-1 alone provides [1].
The upcoming presentation at ENDO 2025 will provide crucial insights into the pharmacokinetic data of OPK-88006, which is essential for further development. However, investors should recognize that this program remains in preclinical stages and requires several years of clinical development before potential commercialization [2].
References:
[1] https://www.stocktitan.net/news/OPK/opko-health-and-entera-bio-abstract-for-first-in-class-dual-glp-1-buci39mc8xnv.html
[2] https://www.globenewswire.com/news-release/2025/06/25/3105023/0/en/OPKO-Health-and-Entera-Bio-Abstract-for-First-in-Class-Dual-GLP-1-Glucagon-Tablet-Candidate-for-Patients-with-Obesity-and-Metabolic-Disorders-Selected-for-Presentation-at-the-ENDO-.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet